Angiotech kept at buy by Merrill

Merrill Lynch analyst Hari Sambasivam maintained Angiotech Pharmaceuticals Inc. at a buy after the company's partner, Boston Scientific, pre-announced third-quarter Taxus sales (which affects Angiotech's fourth quarter), projecting a range of $550 million to $580 million, below Merrill's estimate of $610 million. The analyst estimates a negative impact of $0.02 to his earnings-per-share estimate of $0.16, while Taxus royalties represent 39% of Merrill's revenue estimate for the fourth quarter. Shares of the Vancouver, B.C.-based medical technology company were down $1.17, or 11.17%, at $9.30. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.